No increase in <scp>anti‐A</scp> isohemagglutinin titer after <scp>SARS‐CoV</scp>‐2 infection: A retrospective cohort analysis of group O apheresis platelet donors

Wasiluk, Tomasz; Bujno, Magdalena; Rybinska, Kamila; Rogowska, Anna; Żebrowska, Agnieszka; Boczkowska-Radziwon, Barbara; Piszcz, Jarosław; Bołkuń, Łukasz; Radziwon, Piotr

doi:10.1002/jca.21942

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher susceptibility to SARS-CoV-2 infection because of individually pre-existing low ABO antibody levels facilitating virus attachment to host cells, rather than other dynamic changes in response to the infection, may be suggested. Accordingly, Wasiluk et al failed to find an increase in anti-A IgM titres in platelet concentrates from blood group O donors as determined before and after infection with the virus [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Lower Levels of ABO Anti-A and Anti-B of IgM, IgG and IgA Isotypes in the Serum but Not the Saliva of COVID-19 Convalescents

Matzhold

Körmöczi

Banfi

et al. 2022

JCM

View full text Add to dashboard Cite

Individuals with ABO type O, naturally possessing anti-A and anti-B antibodies in their serum, are underrepresented among patients infected with SARS-CoV-2 compared with healthy controls. The ABO antibodies might play a role in the viral transmission. Therefore, we aimed to quantify anti-A/anti-B, including their subclasses IgM, IgG and IgA, in the serum and saliva of Caucasians (n = 187) after mild COVID-19 to compare them with individuals who had never been infected with SARS-CoV-2. Two samples were collected within two months after the diagnosis (median days: 44) and two months later. ABO antibodies were determined by flow cytometry. Additionally, total IgA in saliva and antibodies specific to SARS-CoV-2 were tested by ELISA. COVID-19 convalescents had significantly lower levels of anti-A/anti-B IgM, IgG and IgA in their serum than control subjects (p < 0.001). Interestingly, no significant differences were observed in saliva. ABO antibody levels remained stable over the period considered. No relation of ABO to the level of SARS-CoV-2-specific antibodies was observed. Total IgA was lower in convalescents than in controls (p = 0.038). Whereas ABO antibodies in the saliva may not contribute to the pathogenesis of COVID-19, individual pre-existing high serum concentrations of anti-A/anti-B may have a protective effect against SARS-CoV-2 infection.

show abstract

Section: Discussionmentioning

confidence: 99%